Article
Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers.
Drug metabolism and disposition: the biological fate of chemicals - 1 Nov 2018
Vanhove Thomas, de Jonge Hylke, de Loor Henriëtte, Oorts Marlies, de Hoon Jan, Pohanka Anton, Annaert Pieter, Kuypers Dirk R J
Abstract excerpt
CYP3A5 genotype is a major determinant of tacrolimus clearance, and has been shown to affect systemic tacrolimus metabolite/parent ratios in healthy volunteers, which may have implications for efficacy and toxicity. In a cohort of 50 renal transplant recipients who underwent quantification of CYP3A4 activity using the oral midazolam drug probe, we confirmed that CYP3A5 genotype is the single most important...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.